drug pricing

Express Scripts' Miller Backs New Pricing Models for CAR-T
Express Scripts' Miller Backs New Pricing Models for CAR-T
BioCentury
Express Scripts
drug pricing
CAR-T
gene therapy
Kymriah
Flag link:
New pharma CEOs to face payer, pricing challenges
New pharma CEOs to face payer, pricing challenges
Medical Marketing and Media
Pharma CEOs
Novartis
Teva Pharmaceutical
Kåre Schultz
Vasant Narasimham
payers
drug pricing
Flag link:
Will Amazon really get into drug sales? It's in talks with PBMs already, report says
Will Amazon really get into drug sales? It's in talks with PBMs already, report says
Fierce Pharma
Amazon
PBMs
supply chain
drug pricing
Flag link:
Judge denies PhRMA, BIO jab at Nevada law
Judge denies PhRMA, BIO jab at Nevada law
BioPharma Dive
PhRMA
BIO
Nevada
drug pricing
Flag link:
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars
Drug Channels
drug pricing
reimbursement
Remicade
biosimilars
Janssen
Inflectra
Pfizer
Renflexis
Merck
Flag link:
Drug Industry Denied Fast Relief in Nevada Price Law Challenge
Drug Industry Denied Fast Relief in Nevada Price Law Challenge
Bloomberg
drug pricing
Nevada
Flag link:
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
Stat
Pharma CEOs
Allergan
Brent Saunders
drug pricing
Restasis
Flag link:
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Motley Fool
JNJ
Remicade
Stelara
drug pricing
Imbruvica
Xarelto
Darzalex
devices
consumer health
Flag link:
Novartis charged much more in the U.S. for some drugs than in other countries
Novartis charged much more in the U.S. for some drugs than in other countries
Stat
Novartis
drug pricing
Flag link:
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
drug pricing
CAR-T
Novartis
Kymriah
Flag link:
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
Forbes
CAR-T
precision medicine
drug pricing
Novartis
Kymriah
Flag link:
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Forbes
Novartis
CAR-T
drug pricing
FDA
acute lymphoblastic leukemia
Kymriah
Joe Jimenez
Flag link:
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Xconomy
Novartis
FDA
CAR-T
drug pricing
Kymriah
acute lymphoblastic leukemia
Flag link:
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight
Fierce Pharma
Gilead Sciences
Kite Pharma
CAR-T
drug pricing
M&A
Flag link:
States Take on Drug Price Transparency, Gouging
States Take on Drug Price Transparency, Gouging
RAPS.org
drug pricing
transparency
Flag link:
New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’
New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’
Stat
CAR-T
Novartis
drug pricing
CTL019
leukemia
Flag link:
In cost debate, Amgen stands by Repatha's value
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Amgen
Repatha
drug pricing
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Flag link:
Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times
Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times
Reuters
Hikma
drug pricing
West-Ward Pharmaceuticals
Flag link:
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing
Fierce Pharma
Novartis
Pharma CEOs
CAR-T
Joe Jimenez
drug pricing
Flag link:
On Drug Pricing: FDA Backs Up Its Calls for Increased Competition
On Drug Pricing: FDA Backs Up Its Calls for Increased Competition
Xconomy
drug pricing
FDA
competition
Flag link: